Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to “Buy” at Wall Street Zen

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Separately, Cantor Fitzgerald upgraded Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $42.00 target price for the company in a report on Wednesday, July 30th.

Supernus Pharmaceuticals Trading Up 1.2%

NASDAQ:SUPN opened at $35.51 on Friday. The firm has a market cap of $1.99 billion, a PE ratio of 31.99 and a beta of 0.74. The stock has a fifty day moving average price of $32.64 and a 200 day moving average price of $33.34. Supernus Pharmaceuticals has a 12-month low of $27.05 and a 12-month high of $40.28.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Envestnet Asset Management Inc. raised its stake in Supernus Pharmaceuticals by 50.2% in the second quarter. Envestnet Asset Management Inc. now owns 90,525 shares of the specialty pharmaceutical company’s stock valued at $2,853,000 after buying an additional 30,256 shares in the last quarter. MQS Management LLC acquired a new stake in Supernus Pharmaceuticals in the second quarter valued at $279,000. AlphaQuest LLC raised its stake in Supernus Pharmaceuticals by 360.0% in the second quarter. AlphaQuest LLC now owns 22,391 shares of the specialty pharmaceutical company’s stock valued at $706,000 after buying an additional 17,523 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Supernus Pharmaceuticals in the second quarter valued at $1,536,000. Finally, Mutual of America Capital Management LLC raised its stake in Supernus Pharmaceuticals by 5.3% in the second quarter. Mutual of America Capital Management LLC now owns 212,691 shares of the specialty pharmaceutical company’s stock valued at $6,704,000 after buying an additional 10,726 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.